# A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

> **NCT04570423** · PHASE2 · RECRUITING · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 40 (estimated)

## Conditions studied

- Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** Eflapegrastim
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT04570423
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-20
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04570423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04570423, "A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04570423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*